<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4574619/results/search/country/results.xml">
  <result pre="asymptomatic circulation of serotype 1 WPV (WPV1) in parts of" exact="Israel" post="despite very high IPV routine immunization coverage strongly suggests"/>
  <result pre="development of symptoms and diagnosis. A study of VAPP in" exact="the US" post="assumed an incidence of approximately 1 PID patient per"/>
  <result pre="incidence of approximately 1 PID patient per 10,000 births in" exact="the US" post="[42]. Intravenous immunoglobulin (IVIG) therapy reduces morbidity and probably"/>
  <result pre="total PID patients (0.1 %) (Table 1). Another child in" exact="Sri Lanka" post="with SCID died while infected and appeared as a"/>
  <result pre="PID patients (0.1 %) (Table 1). Another child in Sri" exact="Lanka" post="with SCID died while infected and appeared as a"/>
  <result pre="excretors iVDPV excretors Patients with &amp;gt; 6 months of documented excretion Source(s)" exact="Bangladesh" post="13 0 1 0 0 [52] Brazil 95 70"/>
  <result pre="documented excretion Source(s) Bangladesh 13 0 1 0 0 [52]" exact="Brazil" post="95 70 3 0 0 [16] China 167 22"/>
  <result pre="0 0 [52] Brazil 95 70 3 0 0 [16]" exact="China" post="167 22 3 0 0 [52] Egypta 15 3"/>
  <result pre="0 0 [52] Egypta 15 3 2 0 0 [21]" exact="Iran" post="43 16 1 0 0 [52] Italy 38 0"/>
  <result pre="0 0 [21] Iran 43 16 1 0 0 [52]" exact="Italy" post="38 0 0 0 0 [17] Mexico 33 5"/>
  <result pre="0 0 [52] Italy 38 0 0 0 0 [17]" exact="Mexico" post="33 5 1 0 0 [16] Philippines 70 6"/>
  <result pre="0 0 [17] Mexico 33 5 1 0 0 [16]" exact="Philippines" post="70 6 1 0 0 [52, 60] Russia 136"/>
  <result pre="0 [16] Philippines 70 6 1 0 0 [52, 60]" exact="Russia" post="136 27 0 0 0 [52] Sri Lanka 51"/>
  <result pre="0 [52, 60] Russia 136 27 0 0 0 [52]" exact="Sri Lanka" post="51 13 5 2 1b [20, 52] Tunisia 16"/>
  <result pre="[52, 60] Russia 136 27 0 0 0 [52] Sri" exact="Lanka" post="51 13 5 2 1b [20, 52] Tunisia 16"/>
  <result pre="[52] Sri Lanka 51 13 5 2 1b [20, 52]" exact="Tunisia" post="16 2 4 0 0 [61] Tunisia 82 14"/>
  <result pre="1b [20, 52] Tunisia 16 2 4 0 0 [61]" exact="Tunisia" post="82 14 6 0 [19, 52] United Kingdom 125"/>
  <result pre="0 0 [61] Tunisia 82 14 6 0 [19, 52]" exact="United Kingdom" post="125 65 0 0 0 [16] United States 94"/>
  <result pre="[19, 52] United Kingdom 125 65 0 0 0 [16]" exact="United States" post="94 75 0 0 0 [16] Total 978 318"/>
  <result pre="retrospective analysis of all 37 immunodeficient VAPP cases reported in" exact="the United States" post="between 1975 and 1997 found 6 months of excretion"/>
  <result pre="analysis of all 37 immunodeficient VAPP cases reported in the" exact="United States" post="between 1975 and 1997 found 6 months of excretion"/>
  <result pre="[62] and approximately 50 % secondarily infected from SIAs in" exact="Oman" post="and Cuba [63, 64], assuming 1 SIA per year"/>
  <result pre="approximately 50 % secondarily infected from SIAs in Oman and" exact="Cuba" post="[63, 64], assuming 1 SIA per year on average"/>
  <result pre="Based on case-fatality rates among 6 immunodeficient VAPP patients in" exact="Iran" post="and 36 immunodeficient VAPP cases in the US; for"/>
  <result pre="VAPP patients in Iran and 36 immunodeficient VAPP cases in" exact="the US;" post="for the latter, we assume that a death within"/>
  <result pre="4 CVID and 33 oPID patients reported with VAPP in" exact="the US" post="during the 23-year period 1975–1997 [53]. Assuming approximately 400"/>
  <result pre="1975–1997 [53]. Assuming approximately 400 annual PID births [42] in" exact="the US" post="and that 20 % of PID patients represent CVIDs"/>
  <result pre="manuscript. RJDT and KMT acknowledge support for this work from" exact="the US" post="Centers for Disease Control and Prevention under Contract U66IP000519."/>
  <result pre="the authors and do not represent the official views of" exact="the US" post="Centers for Disease Control and Prevention. References References 1.World"/>
  <result pre="TebbensRJGrottoIShulmanLMAnisEWassilakSGFPallanschMAThompsonKMModeling options to manage type 1 wild poliovirus imported into" exact="Israel" post="in 2013J Infect Dis20152111118001210.1093/infdis/jiu67425505296 13.Duintjer TebbensRJThompsonKMModeling the potential role"/>
  <result pre="virus carriers among people with primary immune deficiency diseases in" exact="the United States," post="Mexico, Brazil and the United KingdomBull World Health Organ20048213815106294"/>
  <result pre="carriers among people with primary immune deficiency diseases in the" exact="United States," post="Mexico, Brazil and the United KingdomBull World Health Organ20048213815106294"/>
  <result pre="with primary immune deficiency diseases in the United States, Mexico," exact="Brazil" post="and the United KingdomBull World Health Organ20048213815106294 17.FioreLPlebaniAButtinelliGFioreSDonatiVMarturanoJSoresinaAMartireBAzzariCNigroGet al.Search"/>
  <result pre="review of the literatureJ Infect Dis1997175Suppl. 1S1768210.1093/infdis/175.Supplement_1.S1769203713 26.MacCallumFOHypogammaglobulinaemia in the" exact="United Kingdom." post="VII. The role of humoral antibodies in protection against"/>
  <result pre="and inactivated poliovirus vaccines: results of a randomized trial in" exact="The Gambia," post="Oman, and Thailand. WHO Collaborative Study Group on Oral"/>
 </snippets>
</snippetsTree>
